Ligand Pharmaceuticals | LGND - Assets

Stock Price
213.21
Daily Change
-5.77 -2.63%
Monthly
-4.49%
Yearly
103.95%
Q2 Forecast
208.92

Ligand Pharmaceuticals reported $1.53B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Agenus USD 186.46M 40.34M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Anika Therapeutics USD 179.39M 10.88M Mar/2026
Arrowhead Research USD 2.27B 664.08M Mar/2026
Baxter International USD 19.85B 209M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Enviri Corporation USD 2.7B 4.56M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
Intrexon USD 73.16M 77.88M Jun/2024
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Ligand Pharmaceuticals USD 1.53B 28.53M Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Pacira USD 1.21B 56.38M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Veracyte USD 1.44B 30.38M Mar/2026